We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 Feb 2020 14:25

RNS Number : 7873D
4d Pharma PLC
21 February 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

4D PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Société Générale SA (SG SA)

City and country of registered office (if applicable)

Puteaux, France

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

19/02/2020

6. Date on which issuer notified (DD/MM/YYYY):

20/02/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.98%

0.00%

4.98%

65,493,842

Position of previous notification (if

applicable)

5.09%

0.00%

5.09%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJL5BR07

Ordinary shares

3,261,295

0

4.98%

0%

SUBTOTAL 8. A

3,261,295

4.98%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlement

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, United Kingdom

Date of completion

February 20th, 2020

Notes

 

i Please note that national forms may vary due to specific national legislation (Article 3(1a) of Directive 2004/109/EC) as for instance the applicable thresholds or information regarding capital holdings.

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h)/ Article 10 (b) to (h) of Directive 2004/109/EC; (c) all parties to the agreement referred to in Article 10 (a) of Directive 2004/109/EC (DTR5.2.1 (a)) or (d) the holder of financial instruments referred to in Article 13(1) of Directive 2004/109/EC (DTR5.3.1).

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of Directive 2004/109/EC (DTR5.2.1 (b) to (h)), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive (DTR5.2.1 (b)), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive (DTR5.2.1 (c)), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive (DTR5.2.1 (d)), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive (DTR5.2.1 (e)), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9 (DTR 5.1), under letters (a) to (d) of Article 10 of that Directive (DTR5.2.1 (a) to (d)) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive (DTR5.2.1 (f)), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive (DTR5.2.1 (g)), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive (DTR5.2.1 (h)), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive (DTR5.2) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold in accordance with national law, please note that it might not be necessary in accordance with national law to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Article 13(1a) of Directive 2004/109/EC) (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFLFFSFVILFII
Date   Source Headline
16th Feb 20237:00 amRNSCancellation - 4d Pharma Plc
15th Feb 20231:16 pmRNSCancellation of admission to trading on AIM
2nd Feb 20233:10 pmRNSUpdated Results from Renal Cell Carcinoma Cohort
16th Jan 202310:15 amRNSResult of Meeting
30th Dec 202212:30 pmRNSUpdate on Administration and Suspension of Trading
16th Nov 20227:00 amRNSBlautix Phase II Clinical Trial Results Published
10th Nov 20222:00 pmRNSMRx0518 SITC 2022 poster presentations
5th Oct 20221:00 pmRNSMRx0518 poster presentations at SITC 2022
29th Sep 202210:00 amRNSUpdate on Suspension of Trading on AIM
24th Aug 20227:00 amRNSPublication of preclinical autism research
4th Aug 20223:33 pmRNSPublication of Joint Administrators' Proposals
1st Jul 20225:33 pmRNSTemporary Pause of Recruitment in Clinical Trials
28th Jun 20226:28 pmRNS4D Pharma receives Notice of Delisting from NASDAQ
28th Jun 20223:15 pmRNSResult of AGM
27th Jun 20225:30 pmRNS4D Pharma
24th Jun 20226:22 pmRNSUpdate on Suspension of Trading
24th Jun 202212:30 pmRNSSuspension - 4D Pharma PLC
24th Jun 202212:30 pmRNSTemporary Suspension
14th Jun 20227:00 amRNSPre AGM-Investor Presentation and Q&A
7th Jun 202211:00 amRNSExercise of Options and Total Voting Rights
27th May 20227:00 amRNSASCO 2022 MRx0518 and Bavencio Trial In Progress
25th May 20221:51 pmRNSAnnual Report and Notice of AGM
17th May 20227:00 amRNSATS 2022 - MRx-4DP0004 Phase I/II Part A poster
1st Apr 20227:00 amRNSFinal Results
24th Mar 202210:50 amRNSHolding(s) in Company
23rd Mar 20227:00 amRNSMRx0518 + Keytruda - Primary endpoint met in RCC
21st Mar 202210:46 amRNSHolding(s) in Company
9th Mar 20227:00 amRNSForm F3 Registration Statement filed with SEC
24th Feb 20227:21 amRNSHolding(s) in Company
23rd Feb 20227:00 amRNSParticipation in Chardan Microbiome Summit
22nd Feb 20227:00 amRNSParkinson’s trial receives FDA IND clearance
18th Feb 20227:00 amRNSRestatement of Interim Results to June 30, 2021
27th Jan 20227:00 amRNSAdditional MRx04 Phase 1/2 asthma data and event
25th Jan 20225:17 pmRNSHolding(s) in Company
20th Jan 20227:00 amRNS4D pharma to host virtual KOL event
6th Jan 202210:07 amRNSHolding(s) in Company
5th Jan 20227:00 amRNSParticipation in Upcoming Investor Conference
4th Jan 20227:00 amRNS4D pharma appoints John Doyle as CFO
4th Jan 20227:00 amRNSGrant of Options
13th Dec 20217:00 amRNS4D pharma Phase 1/2 asthma study Part A results
9th Dec 20217:00 amRNS4D pharma presents IBS Phase 2 microbiome analysis
7th Dec 20212:19 pmRNSHolding(s) in Company
19th Nov 20215:58 pmRNSHolding(s) in Company
11th Nov 20217:00 amRNS4D pharma Jefferies Healthcare Conference
12th Oct 20217:00 amRNSJefferies Next Generation IBD Therapeutics Summit
30th Sep 20217:00 amRNSHalf-year Report
16th Sep 20212:08 pmRNSHolding(s) in Company
15th Sep 20217:00 amRNS4D pharma presents two posters at ESMO Congress
9th Sep 20217:00 amRNSParticipation in Upcoming Investor Conferences
19th Aug 20219:44 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.